Generic Advair nod helps India's Aurobindo Pharma, raises competition for Cipla, Citi says

Cipla

13/01/2026 06:55

** U.S. FDA approves application for generic version of GSK's Advair inhaler by partner of Aurobindo Pharma-owned ARBN.NS Lannett, Citi says

** Brokerage sees generic Advair adding $30 mln-$40 mln to co's annual U.S. revenues

** Notes additional competition from Aurobindo Pharma "marginal negative" for rival Cipla CIPL.NS, which expects FDA approval for gAdvair in near-term

** Adds Advair seen contributing $50 million to Cipla's U.S. revenue in FY27

** Aurobindo Pharma gets more than 50% of annual revenue from U.S.; Cipla earns ~29% from North America (mostly U.S.)

** Aurobindo Pharma said it would buy U.S.-based Lannett last year at enterprise value of $250 million

** ARBN down 0.6%; CIPL down 1.4%, second-biggest pct loser on Nifty 50 .NSEI

 (Reporting by Nandan Mandayam in Bengaluru)

 ((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))